Antibodies to Abatacept, also called anti-drug antibodies (ADAs), are immune system-generated proteins that recognize and bind to abatacept, potentially neutralizing its therapeutic effects or altering its pharmacokinetics. As abatacept is a biologic agent derived from a human IgG1 fusion protein (CTLA4-Ig), it is less immunogenic than non-human biologics, but ADA formation still occurs in a subset of samples. These antibodies can be binding (non-neutralizing) or neutralizing, with the latter capable of reducing clinical efficacy or increasing the risk of infusion reactions.
This product is manufactured in Turkey by Matriks Biotek.
